WEBINAR
Combining Cell Painting and Transcriptomics Across the Drug Discovery Workflow
Wednesday, Oct 21 2026
16:00 - 17:00 CEST / 10:00 - 11:00 EDT
In this webinar, Axxam and Alithea Genomics present a practical approach that integrates cell painting and transcriptomic profiling from early target discovery through preclinical safety assessment.
Using real-world case studies, including CRISPR-based target validation and toxicology applications, we will show how scalable phenotypic screening and deep molecular characterization can be deployed together to generate high-quality, actionable data. Attendees will gain insight into experimental design, data generation strategies, and the advantages of combining complementary technologies across multiple stages of discovery.
Riccardo is the CBO and co-founder of Alithea Genomics.
Before that, he completed his PhD in Bioengineering and Microfluidics at the Swiss Federal Institute of Technology (EPFL) in the Laboratory of Systems Biology and Genetics run by Prof. Bart Deplancke.
During his PhD Riccardo has worked on and co-developed a number of microvalve-based and droplet-based microfluidic devices with genomic applications, such as Smile-seq, FloChIP, DisCO all of which have been patented separately and published in top-tier journals such as Nature Methods and PNAS.
Before his PhD, Riccardo obtained a Master’s degree in Nanotechnology at Chalmers University (Goteborg, Sweden) and a Bachelor’s in Biomedical Engineering at the Politecnico di Torino (Italy).
Roberto Ravasio is Principal Scientist in the Advanced Cellular Assay group at Axxam, where he leads multidisciplinary drug discovery projects for biotech and pharmaceutical partners. His expertise spans cell and molecular biology, functional genomics, molecular assay development, and phenotypic and omics-based profiling, with a particular focus on Cell Painting and transcriptomics. By integrating complementary technologies and multidimensional datasets, his work supports target discovery and validation, compound profiling, and in vitro preclinical safety assessment, translating complex biological readouts into actionable insights across the drug discovery workflow.
Roberto obtained his BSc and MSc from the University of Milan and completed his PhD and postdoctoral research at the European Institute of Oncology in Milan, where he focused on functional genomics and omics approaches for drug discovery and translational research.
